Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Coopervision, Inc. Identifier:
First received: August 2, 2013
Last updated: January 12, 2017
Last verified: January 2017
The purpose of the study is to quantify the effectiveness of CooperVision MiSight® (omafilcon A) soft (hydrophilic) contact lens in slowing the rate of progression of juvenile-onset myopia.

Condition Intervention Phase
Device: omafilcon A
Device: Spectacle
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial.

Resource links provided by NLM:

Further study details as provided by Coopervision, Inc.:

Primary Outcome Measures:
  • Change in the spherical equivalent refractive error relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ]
  • Change in axial length relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ]
  • Measurement of corneal curvature (keratometry)relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ]

Secondary Outcome Measures:
  • Measurement of pupil diameter relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ]

Enrollment: 80
Study Start Date: September 2013
Estimated Study Completion Date: January 2017
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: omafilcon A
Contact Lens Group
Device: omafilcon A
Active Comparator: Spectacle Group
Prescription at Baseline
Device: Spectacle


Ages Eligible for Study:   8 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Prior to being considered eligible to participate in this study, each subject MUST:

    1. Be between 8 and 12 years of age inclusive at the baseline examination.
    2. Have:

      1. read the Informed Assent,
      2. been given an explanation of the Informed Assent,
      3. indicated an understanding of the Informed Assent and
      4. signed the Informed Assent Form.
    3. Have their parent or legal guardian:

      1. read the Informed Consent,
      2. been given an explanation of the Informed Consent,
      3. indicated an understanding of the Informed Consent and
      4. signed the Informed Consent Form.
    4. Along with their parent or guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to the instructions set forth in this protocol.
    5. Along with their parent or guardian, agree to maintain the visit schedule and be able to keep all appointments as specified in the study protocol for the duration of the study
    6. Agree to accept either the control or test lens as assigned by the randomisation scheme.
    7. Agree to wear the assigned contact lenses for a maximum of 15 hours per day, , for the duration of the 2 year study and to inform the study investigator if this schedule is interrupted. (Wearing time may be modified by the study staff for health reasons.)
    8. Possess wearable and visually functional eyeglasses.
    9. Be in good general health, based on his/her and parent's/guardian's knowledge.
    10. Have best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye.
    11. Meet the following refractive criteria determined by cycloplegic autorefraction at baseline:

      1. Spherical Equivalent Refractive Error (SERE): between -0.75 and -4.00 D inclusive.
      2. Astigmatism: < -0.75 D
      3. Anisometropia: < 1.00D

Exclusion Criteria:

  • Subjects may not be considered eligible if ANY of the following apply:

    1. Subject has previously or currently wears contact lenses or rigid gas permeable contact lenses, including orthokeratology lenses.
    2. Subject appears to exhibit poor personal hygiene (that in the investigator's opinion might prevent safe contact lens wear).
    3. Subject is currently or prior to this study has been an active participant in another clinical study.
    4. Parent / guardian or close relative is a member, of the office staff, including the investigator(s).
    5. Current or prior use of bifocals, progressive addition lenses, atropine, pirenzepine or ANY other myopia control treatment.
    6. Subject was born earlier than 30 weeks or weighed less than 1500g (3.3lb) at birth.
    7. Regular use of ocular medications (prescription or over-the-counter), artificial tears, or wetting agents.
    8. Current use of systemic medications which may significantly affect contact lens wear, tear film production, pupil size, accommodation or refractive state. Such as, but not limited to: long term use of nasal decongestants (for example, pseudoephedrine, phenylephrine), antihistamines (for example, chlorpheniramine, diphenhydramine), Prednisolone or Ritalin (methylphenidate).
    9. A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.
    10. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.
    11. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction.
    12. Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjogren's syndrome, lupus erythematosus, scleroderma, or diabetes.
    13. Any ocular, systemic or neuro-developmental conditions that could influence refractive development. Such as, but not limited to: persistent pupillary membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis eyelid hemangiomas, Marfan's Syndrome, Down's syndrome, Ehler's-Danlos syndrome, Stickler's syndrome, ocular albinism, retinopathy of prematurity.
    14. Keratoconus or an irregular cornea.
    15. Biomicroscope findings that would contraindicate contact lens wear including, but not limited to:

      1. corneal scars within the visual axis
      2. neovascularisation or ghost vessels > 1.5 mm in from the limbus
      3. Any active anterior segment ocular disease that would contraindicate contact lens wear.
      4. giant papillary conjunctivitis of Grade 2 or worse
      5. allergic or seasonal conjunctivitis (if the study investigator believes it could significantly interfere with maintaining the specified contact lens wearing schedule)
      6. clinically significant (Grade 3 or 4) abnormalities of the anterior segment, lids, conjunctiva, sclera or associated structures.
    16. The investigator for any reason considers that it is not in the best interest of the subject to participate in the study.
    17. Have pathological myopia To be eligible to begin the study, a subject must have ALL of the inclusion criteria and NONE of the exclusion criteria present.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01917110

Departamento de Óptica y Optometría de la Universidad Europea de Madrid
Madrid, Spain
Sponsors and Collaborators
Coopervision, Inc.
Principal Investigator: Cesar Villa Collar, PhD Departamento de Optica y Optometria de la Universidad Europea de Madrid
  More Information

Responsible Party: Coopervision, Inc. Identifier: NCT01917110     History of Changes
Other Study ID Numbers: P2013/05
Study First Received: August 2, 2013
Last Updated: January 12, 2017

Additional relevant MeSH terms:
Refractive Errors
Eye Diseases processed this record on May 25, 2017